Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.57 |
| ▸ | HTR1A | P08908 | 6/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.57 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200156 | 0.83 | HTR1A (0.37) | SLC6A4HTR1ASLC6A2SLC6A3TNKS2 | |
| SCHEMBL2204690 | 0.83 | SLC6A2 (0.46) | SLC6A4HTR1ASLC6A2SLC6A3HTR2C | |
| SCHEMBL4720203 | 0.81 | HTR2B (0.45) | SLC6A4HTR1ASLC6A2SLC6A3HTR2C | |
| SCHEMBL4723022 | 0.80 | TP53 (0.41) | SLC6A4HTR1ASLC6A2SLC6A3HTR2C | |
| SCHEMBL1254378 | 0.79 | HTR2C (0.51) | SLC6A4HTR1ASLC6A2SLC6A3HTR2C | |
| SCHEMBL11558603 | 0.75 | SLC6A4 (0.59) | SLC6A4HTR1ASLC6A2SLC6A3TNKS2 | |
| SCHEMBL23228732 | 0.73 | SLC6A2 (1.00) | SLC6A4HTR1ASLC6A2SLC6A3HTR2C | |
| SCHEMBL9158101 | 0.70 | HTR2C (0.49) | SLC6A4HTR1ASLC6A2SLC6A3HTR2C | |
| SCHEMBL2204913 | 0.70 | HTR2C (0.47) | SLC6A4HTR1ASLC6A2TNKS2HTR2C | |
| SCHEMBL3549378 | 0.70 | KDM1A (0.42) | SLC6A4HTR1ASLC6A2SLC6A3TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458111-B2 | Process for the synthesis of substituted urea compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-10-04 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20150197503-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL PORTELA & Cª S A (PT) | 2015-07-16 | — | — | US | disclosed |
| EP-2882712-A2 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - Portela & Cª S.A. (PT) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014017938-A2 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2014-01-30 | — | — | WO | disclosed |
| EP-2606035-A1 | PROCES FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - Portela & CA., S.A. (PT) | 2013-06-26 | — | — | EP | disclosed |
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2013-05-16 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| WO-2012015324-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2012-02-02 | — | — | WO | disclosed |
| EP-2382012-A2 | PHARMACEUTICAL COMPOUNDS | Bial-Portela & CA, S.A. (PT) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010074588-A2 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | UTS2R, ARG1, PRMT1 | SLC6A4 3480/4885HTR1A 2947/4885SLC6A2 2598/4885 |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | SLC6A4 1174/4885HTR1A 574/4885SLC6A2 1196/4885 |
| US-20150197503-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | REN, F12, HAT1 | SLC6A4 4332/4885HTR1A 3552/4885SLC6A2 3462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.